• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Surgalign Holdings Inc. (Amendment)

    2/4/22 3:09:26 PM ET
    $SRGA
    Industrial Specialties
    Health Care
    Get the next $SRGA alert in real time by email
    SC 13D/A 1 formsc13da.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

     

    Surgalign Holdings, Inc.

    (Name of Issuer)

     

     

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    86882C105

    (CUSIP Number)

     

    Pawel Lewicki

    296 Woodward Blvd.

    Tulsa, Oklahoma 74114

    (918) 513-2636

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    December 30, 2021

    (Date of Event Which Requires Filing of this Statement)

     

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

     

     

    NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

     

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 86882C105

     

    1.

    Names of Reporting Persons

     

    Pawel Lewicki

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) [ ] (b) [ ]

     

    3.

    SEC Use Only

     

    4.

    Source of Funds (See Instructions)

     

    OO (See Item 3)

    5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) [ ]

     

    6.

    Citizenship or Place of Organization

     

    U.S.

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

    7.

    Sole Voting Power

     

    14,062,531

    8.

    Shared Voting Power

     

    0

    9.

    Sole Dispositive Power

     

    14,062,531

    10.

    Shared Dispositive Power

     

    0

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    14,062,531

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) [ ]

     

    13.

    Percent of Class Represented by Amount in Row (11)

    9.04%*

    14.

    Type of Reporting Person (See Instructions)

     

    IN

     

    *Based on 155,503,027 shares of the Issuer’s common stock outstanding as of February 2, 2022.

     

     

     

     

    Item 3. Source and Amount of Funds or Other Consideration

     

    3,410,396 shares of the Issuer’s common stock were issued to Mr. Lewicki on December 30, 2021 in exchange for the sale of Mr. Lewicki’s minority interest in Inteneural Networks, Inc. to the Issuer.

     

    3,593,750 shares of the Issuer’s common stock were issued to Mr. Lewicki upon achievement of a milestone pursuant to that Second Amendment to Stock Purchase Agreement dated January 14, 2022 between the Issuer, Roboticine, Inc, Holo Surgical S.A, Mr. Lewicki and Krzysztof Siemionow, MD, PhD.

     

    Item 5. Interest in Securities of the Issuer

     

      a) The 14,062,531 shares of common stock beneficially owned by Mr. Lewicki constitutes approximately 9.04% of the Issuer’s outstanding shares of common stock based on 155,503,027 shares of common stock outstanding as of February 2, 2022.

     

      b) Mr. Lewicki has the sole power to vote or direct the vote, and dispose or direct the disposition, of all shares of common stock reported on this Amendment No. 2 to Schedule 13D.

     

      c) The information contained in Item 3 to this Amendment No. 2 to Schedule 13D is incorporated by reference herein. Previous Reporting Person Roboticine, Inc. has been dissolved, and all shares of the Issuer’s common stock previously reported as being beneficially owned by Roboticine, Inc. were distributed directly to Mr. Lewicki and Roboticine, Inc.’s other equityholder. Also, as a result of the dissolution of Roboticine, shares of common stock of the Issuer deemed to be beneficially owned by Neva, LLC and SSAR Investments, LLC are now reported as beneficially owned by Mr. Lewicki. Other than the acquisition of the shares of common stock as reported in Item 3 to this Amendment No. 2 to Schedule 13D, Mr. Lewicki has not effected any transactions in the Issuer’s common stock in the past 60 days.

     

      d) To the Reporting Person’s knowledge, no person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such shares owned directly by Mr. Lewicki, other than Mr. Lewicki.

     

      e) Not applicable.

     

     

     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 4, 2022

     

    /s/ Pawel Lewicki  
    Pawel Lewicki  

     

    ATTENTION
    Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

     

     

    Get the next $SRGA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SRGA

    DatePrice TargetRatingAnalyst
    9/28/2021$1.50Buy → Hold
    Craig Hallum
    More analyst ratings

    $SRGA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Surgalign Receives NASDAQ Delisting Notice Following its Chapter 11 Filing

      DEERFIELD, Ill., June 23, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, announced today that on June 22, 2023, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq"). Nasdaq has determined that due to the Company's voluntary petition for relief under chapter 11 of the U.S. Bankruptcy Code, the Company's securities will be delisted from The Nasdaq Stock Market. The Company does not intend to appeal Nasdaq's determination. As previously announced, Surgalign entered into an asset purchase agreement to

      6/23/23 8:30:00 AM ET
      $SRGA
      Industrial Specialties
      Health Care
    • Surgalign Enters Into Definitive Agreement to Sell Global Hardware and Biologics Business Through a Structured Sale Process Under Chapter 11 of the U.S. Bankruptcy Code

      DEERFIELD, Ill., June 20, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) ("Surgalign" or the "Company") a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced that the Company has entered into an asset purchase agreement (the "Asset Purchase Agreement") to sell substantially all of its U.S. hardware and biomaterials assets and the equity interests in non-Debtor entities related to the Debtors' hardware business outside of the U.S. to Xtant Medical Holdings, Inc. ("Xtant") for $5.0 million. The sale will be effectuated through the chapter 11 proceedings initiated by the Company and certain o

      6/20/23 8:30:00 AM ET
      $SRGA
      Industrial Specialties
      Health Care
    • Surgalign to Participate at ISASS 2023 – 23rd Annual Conference Sponsored by the International Society for the Advancement of Spine Surgery and Medical Education Resources

      Company to showcase its upgraded HOLO Portal™ Surgical Guidance System and key products in its hardware spine and biologics portfolio DEERFIELD, Ill., May 23, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, announced today that it will be exhibiting at ISASS 2023 – the 23rd Annual Conference – sponsored by the International Society for Spine Surgery ("ISASS") and Medical Education Resources. This three-day event will take place June 1-3, 2023 at the Marriott Marquis in San Francisco, CA. The International Society for the Advancement of Spine Surgery i

      5/23/23 8:30:00 AM ET
      $SRGA
      Industrial Specialties
      Health Care

    $SRGA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Surgalign Holdings downgraded by Craig Hallum with a new price target

      Craig Hallum downgraded Surgalign Holdings from Buy to Hold and set a new price target of $1.50

      9/28/21 7:57:45 AM ET
      $SRGA
      Industrial Specialties
      Health Care
    • BTIG Research initiated coverage on Surgalign Holdings with a new price target

      BTIG Research initiated coverage of Surgalign Holdings with a rating of Buy and set a new price target of $4.00

      2/3/21 7:33:38 AM ET
      $SRGA
      Industrial Specialties
      Health Care
    • BTIG Research initiated coverage on Surgalign

      BTIG Research initiated coverage of Surgalign with a rating of Buy

      2/3/21 7:28:58 AM ET
      $SRGA
      Industrial Specialties
      Health Care

    $SRGA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Surgalign Holdings Inc. (Amendment)

      SC 13G/A - SURGALIGN HOLDINGS, INC. (0001760173) (Subject)

      2/14/24 2:57:21 PM ET
      $SRGA
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Surgalign Holdings Inc.

      SC 13G - SURGALIGN HOLDINGS, INC. (0001760173) (Subject)

      2/14/23 1:32:27 PM ET
      $SRGA
      Industrial Specialties
      Health Care
    • SEC Form SC 13D/A filed by Surgalign Holdings Inc. (Amendment)

      SC 13D/A - SURGALIGN HOLDINGS, INC. (0001760173) (Subject)

      2/4/22 3:09:26 PM ET
      $SRGA
      Industrial Specialties
      Health Care

    $SRGA
    Financials

    Live finance-specific insights

    See more
    • Surgalign Schedules First Quarter 2023 Earnings Release for May 11, 2023

      DEERFIELD, Ill., May 04, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced its plans to release financial results for its first quarter 2023 after the close of trading on May 11, 2023. Surgalign will host a conference call and audio webcast at 4:30 p.m. ET the same day. The conference call can be accessed by dialing (888) 437-3179 (U.S.) or 862-298-0702 (International). The webcast can be accessed through the investor relations section of Surgalign's website at www.surgalign.com/investors. A replay of the conference call will be available

      5/4/23 8:30:00 AM ET
      $SRGA
      Industrial Specialties
      Health Care
    • Xtant Medical Acquires Coflex® Product Line from Surgalign for $17 Million

      Expands Xtant's Product Offering with the Leading PMA-Approved Intralaminar Stabilization Device Strengthens Surgalign's Balance Sheet as it Embarks on its Digital Health Strategy BELGRADE, Mont. and DEERFIELD, Ill., March 01, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, and Surgalign Holdings, Inc., (NASDAQ:SRGA), a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, today announced the completion of a transaction between the companies. On February 28, 2023, Xtant Medical and Surgalign entered

      3/1/23 9:15:00 AM ET
      $SRGA
      $XTNT
      Industrial Specialties
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Surgalign Announces Third Quarter 2022 Results and Provides Update on Business Operations and Financial Outlook

      DEERFIELD, Ill., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, today announced financial results for its 2022 third quarter ended September 30, 2022. 2022 Third Quarter Corporate Highlights: Two new clinical sites in Ohio utilize the HOLO PortalTM surgical guidance system.FDA 510(k) clearance of the Cortera™ Spinal Fixation System, the first organically designed product by Surgalign.Expansion of the Fortilink® product portfolio with TiPlus™ technology products.Settlements with Resolve Surgical Technologies and RTI Surgical, Inc., and with

      11/2/22 4:01:00 PM ET
      $SRGA
      Industrial Specialties
      Health Care

    $SRGA
    Leadership Updates

    Live Leadership Updates

    See more
    • Surgalign Names Paolo Amoruso Chief Legal Officer and Corporate Secretary

      DEERFIELD, Ill., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced the appointment of Paolo Amoruso as its new General Counsel and Corporate Secretary, effective August 1, 2022. He previously served as Interim General Counsel of Surgalign, having joined the Company in April 2022. Commenting on today's appointment, Terry Rich, President and Chief Executive Officer of Surgalign stated, "Paolo has been an invaluable member of our team since taking on the role of Interim General Counsel just a few months ago. He has quickly immersed

      8/4/22 8:30:00 AM ET
      $SRGA
      Industrial Specialties
      Health Care
    • Surgalign Announces Appointment of David Lyle as Chief Financial Officer

      DEERFIELD, Ill., March 07, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc. (NASDAQ:SRGA) ("Surgalign"), a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced the appointment of David Lyle, as Chief Financial Officer, effective immediately. "David brings a wealth of experience in helping to guide the growth of technologies to Surgalign at an important and exciting inflection point of the company's evolution," said Terry Rich, Surgalign's president and chief executive officer. "David is joining Surgalign at a critical time as we transition to the early commercial stage of our HOLO AI technology platform, w

      3/7/22 9:00:00 AM ET
      $SRGA
      Industrial Specialties
      Health Care
    • Anika Appoints Sheryl Conley to Board of Directors

      BEDFORD, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that its Board of Directors has appointed Sheryl Conley as independent director, effective October 28, 2021. Sheryl Conley joins the Anika Board of Directors with over 35 years of orthopedic and healthcare industry experience, most recently as President and CEO of OrthoWorx, Inc., and previously as Group President, Americas and Global Brand Management, and Chief Marketing Officer for Zimmer, Inc. Ms. Conley brings extensive orthopedic medical device industry knowledge with a focus on global brand management

      11/1/21 9:00:00 AM ET
      $ANIK
      $SRGA
      $STIM
      Medical/Dental Instruments
      Health Care
      Industrial Specialties

    $SRGA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Lyle David covered exercise/tax liability with 1,329 shares, decreasing direct ownership by 2% to 83,307 units

      4 - SURGALIGN HOLDINGS, INC. (0001760173) (Issuer)

      9/18/23 11:47:26 AM ET
      $SRGA
      Industrial Specialties
      Health Care
    • SEC Form 4: Amoruso Paolo covered exercise/tax liability with 2,191 shares, decreasing direct ownership by 7% to 28,809 units

      4 - SURGALIGN HOLDINGS, INC. (0001760173) (Issuer)

      9/5/23 10:20:10 AM ET
      $SRGA
      Industrial Specialties
      Health Care
    • SEC Form 4: Thunander Christopher covered exercise/tax liability with 2,295 shares, decreasing direct ownership by 8% to 26,039 units

      4 - SURGALIGN HOLDINGS, INC. (0001760173) (Issuer)

      8/16/23 5:36:00 PM ET
      $SRGA
      Industrial Specialties
      Health Care

    $SRGA
    SEC Filings

    See more
    • SEC Form 15-12G filed by Surgalign Holdings Inc.

      15-12G - SURGALIGN HOLDINGS, INC. (0001760173) (Filer)

      11/13/23 4:08:28 PM ET
      $SRGA
      Industrial Specialties
      Health Care
    • SEC Form EFFECT filed by Surgalign Holdings Inc.

      EFFECT - SURGALIGN HOLDINGS, INC. (0001760173) (Filer)

      10/10/23 12:15:07 AM ET
      $SRGA
      Industrial Specialties
      Health Care
    • SEC Form EFFECT filed by Surgalign Holdings Inc.

      EFFECT - SURGALIGN HOLDINGS, INC. (0001760173) (Filer)

      10/10/23 12:15:09 AM ET
      $SRGA
      Industrial Specialties
      Health Care